China SXT Pharmaceuticals, Inc. (SXTC) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

China SXT Pharmaceuticals, Inc. (SXTC) Healthcare & Pipeline Overview

China SXT Pharmaceuticals focuses on traditional Chinese medicine pieces (TCMP), offering a range of products under established brands like Suxuantang. Operating in the Chinese pharmaceutical market, the company serves pharmaceutical companies, pharmacies, hospitals, and distributors with advanced, fine, and regular TCMP products and raw medicinal materials.

What Is the Investment Thesis for SXTC?

Investing in China SXT Pharmaceuticals presents a high-risk, high-reward scenario. The company operates in the growing traditional Chinese medicine market, but its negative profit margin of -274.4% raises concerns about its financial stability. A potential investment thesis hinges on the company's ability to improve its operational efficiency and capitalize on the increasing demand for TCMP products. Key value drivers include expanding its product offerings, strengthening its distribution network, and achieving profitability. The company's beta of 1.75 indicates higher volatility compared to the broader market. Investors should closely monitor the company's financial performance and its ability to execute its growth strategy.

Based on FMP financials and quantitative analysis

SXTC Key Highlights

Market capitalization of $1.94M indicates a micro-cap company with limited financial resources.

• Negative profit margin of -274.4% suggests significant operational challenges and potential financial instability.
• Gross margin of 25.5% indicates the company's ability to generate revenue from its products after accounting for the cost of goods sold.
• Beta of 1.75 suggests the stock is more volatile than the market, potentially offering higher returns but also higher risk.
• The company operates in the traditional Chinese medicine market, which is experiencing growth due to increasing consumer interest in natural remedies.

Who Are SXTC's Competitors?

SXTC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SXTC's Key Strengths?

Established brands in the TCM market.

• Diverse product range of TCMP and raw materials.
• Distribution network covering various customer segments.
• Focus on traditional Chinese medicine, a growing market.

What Are SXTC's Weaknesses?

Negative profit margin indicates financial instability.

• Limited market capitalization restricts growth potential.
• High beta suggests volatile stock performance.
• Dependence on the Chinese market.

What Could Drive SXTC Stock Higher?

Potential regulatory approvals for new TCMP products.

• Increasing demand for traditional Chinese medicine in China.
• Government support for the TCM industry.

What Are the Key Risks for SXTC?

Financial-distress signal — its Altman Z-Score of -0.79 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-31.0%) — the business is not currently generating profit on shareholder capital.
• Intense competition from other TCM manufacturers.
• Fluctuations in raw material prices.
• Negative profit margin and financial instability.
• Changes in government regulations affecting the TCM industry.

What Are the Growth Opportunities for SXTC?

• Expanding product offerings: China SXT Pharmaceuticals can grow by developing new TCMP products and formulations to cater to diverse consumer needs. The market for TCM products is constantly evolving, with new ingredients and applications being discovered. By investing in research and development, the company can introduce innovative products that address specific health concerns and gain a competitive edge.
• Strengthening distribution network: The company can enhance its market reach by expanding its distribution network to cover more regions and channels. This includes partnering with more pharmaceutical companies, chain pharmacies, hospitals, and pharmaceutical distributors. By increasing its distribution points, China SXT Pharmaceuticals can make its products more accessible to consumers and drive sales growth. The company can also explore online channels to reach a wider audience and capitalize on the growing e-commerce market in China.
• Improving operational efficiency: China SXT Pharmaceuticals can improve its profitability by streamlining its operations and reducing costs. This includes optimizing its manufacturing processes, improving its supply chain management, and reducing its administrative expenses. By becoming more efficient, the company can improve its gross margin and profit margin, making it more attractive to investors. The company can also invest in automation and technology to further improve its operational efficiency.
• Capitalizing on government support: The Chinese government has been actively promoting the development of the TCM industry, providing financial support and regulatory incentives to TCM manufacturers. China SXT Pharmaceuticals can leverage these government initiatives to accelerate its growth and expand its market share. This includes applying for government grants, participating in government-sponsored research programs, and complying with government regulations. By aligning its business strategy with government policies, the company can gain a competitive advantage and access valuable resources.
• Exploring international markets: While China SXT Pharmaceuticals' primary focus is on the Chinese market, the company can explore opportunities to expand its operations to international markets. TCM is gaining popularity in other countries, particularly in Southeast Asia and Europe. By exporting its products to these markets, the company can diversify its revenue streams and reduce its reliance on the Chinese market. However, the company must navigate different regulatory requirements and cultural preferences in each market.

What Threats Does SXTC Face?

• Intense competition from other TCM manufacturers.
• Stringent regulations and evolving consumer preferences.
• Potential fluctuations in raw material prices.
• Economic downturn in China affecting consumer spending.

What Are SXTC's Competitive Advantages?

• Established brands: Suxuantang, Hui Chun Tang, and Tong Ren Tang brands have recognition in the TCM market.
• Product range: Offers a variety of TCMP products and raw medicinal materials.
• Distribution network: Serves pharmaceutical companies, pharmacies, hospitals, and distributors.

What Does SXTC Do?

China SXT Pharmaceuticals, Inc., established in 2005 and headquartered in Taizhou, China, is a pharmaceutical company specializing in traditional Chinese medicine pieces (TCMP). The company engages in the entire value chain, from research and development to manufacturing, marketing, and sales of TCMP products. Its product portfolio includes advanced, fine, and regular TCMP, along with raw medicinal materials such as SanQiFen, HongQi, and others. These products are marketed under the brands Suxuantang, Hui Chun Tang, and Tong Ren Tang. China SXT Pharmaceuticals serves a diverse customer base, including pharmaceutical companies, chain pharmacies, hospitals, and pharmaceutical distributors. The company's focus on TCMP reflects the growing demand for traditional medicine in China, driven by cultural preferences and perceived health benefits. By offering a range of TCMP products and raw materials, China SXT Pharmaceuticals aims to cater to different segments within the traditional medicine market. The company's operations are primarily based in China, leveraging the country's rich history and resources in traditional medicine.

What Products and Services Does SXTC Offer?

• Researches and develops traditional Chinese medicine pieces (TCMP).
• Manufactures a variety of TCMP products.
• Markets TCMP products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands.
• Sells TCMP products to pharmaceutical companies, chain pharmacies, and hospitals.
• Distributes TCMP products through pharmaceutical distributors.
• Offers advanced, fine, and regular TCMP products.
• Provides raw medicinal materials, such as SanQiFen and HongQi.

How Does SXTC Make Money?

• Develops and manufactures traditional Chinese medicine pieces (TCMP).
• Sells TCMP products to pharmaceutical companies, pharmacies, hospitals, and distributors.
• Generates revenue from the sale of TCMP products and raw medicinal materials.

What Industry Does SXTC Operate In?

China SXT Pharmaceuticals operates within the Drug Manufacturers - Specialty & Generic industry, which is a segment of the broader healthcare sector. The traditional Chinese medicine (TCM) market in China is experiencing growth, driven by increasing consumer awareness and demand for natural and alternative therapies. However, the industry is also characterized by intense competition, stringent regulations, and evolving consumer preferences. Companies in this sector must navigate complex regulatory approval processes and adapt to changing market dynamics to remain competitive. China SXT Pharmaceuticals' focus on TCMP positions it within a niche segment of the TCM market, but it faces competition from larger pharmaceutical companies and other TCM manufacturers.

Who Are SXTC's Key Customers?

• Pharmaceutical companies
• Chain pharmacies
• Hospitals
• Pharmaceutical distributors

China SXT Pharmaceuticals, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.79 places it in the distress zone, a signal of elevated financial risk.

Return on equity for China SXT Pharmaceuticals, Inc. stands at -31.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -21.2%, showing how much profit it generates from its asset base. A current ratio of 7.93 indicates the company holds enough short-term assets to cover its near-term obligations.

China SXT Pharmaceuticals, Inc. (SXTC) Valuation Context

Valued at $1.94M, SXTC is classified as a micro-cap stock. Relative to its peer group, SXTC's quantitative score of 46/100 is below the peer average of 62/100.

SXTC Revenue & Earnings Trend

In Q1 2026, SXTC generated $1.2M in top-line revenue, marking a sequential increase of 368.6%. The company recorded net income of $164K, with diluted EPS of $0.14. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, SXTC averaged $-2.12 in diluted EPS.

Company Profile

China SXT Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Taizhou, CN. The company is led by CEO Feng Zhou. SXTC has traded publicly since 2019.

SXTC Financials

SXTC Latest News

SXTC Analyst Consensus

SXTC MoonshotScore

Latest China SXT Pharmaceuticals, Inc. Analysis

SXTC Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources